Fibroblasts can easily be cultured from human solid ovarian tumor biopsies and are readily transfected using retroviral vectors. To test the feasibility of using these cells as a vehicle for regional, intraperitoneal (i.p.) ovarian cancer gene therapy, we first examined the behavior of murine fibroblasts transduced with the neo R marker gene and injected i.p. in syngeneic mice. We found that these fibroblasts were not invasive and formed clusters preferentially attached to the pancreatic and hepatic mesentery, where they survived for at least 30 days and continued to express neo R . We subsequently assessed the effect of regional delivery of murine interleukin-12 (mIL-12)-secreting fibroblasts in a syngeneic immunocompetent mouse model of ovarian cancer (ID8). ID8 ovarian tumor cells were injected i.p. into one flank. Our results show a survival of 88% at 120 days postinjection of animals treated with mIL-12-secreting fibroblasts i.p. in the other flank on the same day as injection of tumor cells. At that time, all animals coinoculated with ID8 cells and unmodified fibroblasts had been or needed to be culled because of advanced neoplastic disease (P Ͻ 10 Ϫ5 , log-rank test). Furthermore, animals treated with mIL-12-secreting fibroblasts had a statistically significant decrease in tumor burden, as measured by diaphragm weight, relative to mock-treated groups (P ϭ .0032, H-test). Our histological data show evidence for both immunological and anti-angiogenic mechanisms being implicated in this antitumoral effect. In addition, no signs of IL-12-induced toxicity were observed in any of the tissue sections analyzed. Taken together, our findings suggest that ovarian tumor biopsy-derived fibroblasts are a safe and efficacious vehicle for i.p. delivery of IL-12 as a regional secondary treatment for minimal residual disease of ovarian cancer. Cancer Gene Therapy (2000) 7, 707-720
O varian cancer is a highly lethal disease. As in many Western countries, it is the fourth leading cause of cancer mortality among French women, after breast, colorectal, and lung cancer. 1 Due to the asymptomatic course of the early stages of the disease, the majority of these cancers are diagnosed at an advanced stage (International Federation of Gynecology and Obstetrics stage III or IV), with extensive spread of the tumor in the peritoneal cavity. At these stages, surgery can only debulk, and not completely remove, the tumor mass. Current follow-up treatment, generally chemotherapy, is often inadequate for the prevention of recurrence and further tumor progression. 2 Therefore, there is a need to develop additional therapeutic modalities. Gene therapy may eventually complement existing ovarian cancer therapies to treat minimal residual disease. [3] [4] [5] [6] [7] Despite considerable efforts, most in vivo gene delivery systems lack tumor specificity, and the efficiency of gene transfer and expression unfortunately remains low. 8, 9 Instead of in vivo gene therapy, where a vector containing therapeutic genes is injected directly into the patient, one could explore ex vivo gene therapy, which consists of removing target cells from the body, transfecting them with therapeutic genes, and reinjecting these genetically engineered cells into the patient. Ex vivo introduction into tumor cells of the genes encoding immunomodulatory molecules such as cytokines (e.g., interleukins (ILs), interferons) or immune-costimulatory ligands (e.g., CD80) 10 -13 or of enzymes catalyzing the modification of administered nontoxic prodrugs into toxic products ("suicide" gene therapy) 11, 14 has resulted in an inhibition of tumor growth or complete tumor rejection in a variety of animal models.
One of the cytokines that has been used successfully in many tumor models is the heterodimeric (p35 and p40 subunits) protein IL-12. Animal studies have revealed that IL-12 has powerful antitumoral, antimetastatic, and anti-angiogenic activities. [15] [16] [17] [18] This potent antitumoral effect of IL-12 seems to depend upon stimulation of the immune system via direct activation of antitumoral natural killer cells and T lymphocytes, which express specific IL-12 receptors. 19, 20 An important indirect mechanism of action is provided by the resulting secretion of interferon-␥ by these cells, which increases antigen presentation [21] [22] [23] and induces tertiary secretion of anti-angiogenic factors. 24 -26 The aforementioned activities of IL-12 suggest that this cytokine is a good candidate for ex vivo cancer gene therapy strategies. However, a major obstacle to this approach in the case of human ovarian cancer is the difficulty of culturing ovarian tumor cells ex vivo from tumor biopsies, and, to a lesser extent, malignant ascites. 27 , 28 We have shown that fibroblast-like cells can readily be cultured from human solid ovarian tumor biopsies, in contrast to epithelial ovarian tumor cells. The objective of our study was therefore to test the feasibility of using these fibroblasts as a vehicle for regional, intraperitoneal (i.p.) cytokine gene therapy for ovarian cancer. This article describes the characterization of these human biopsy-derived cells and their transduction with a polycistronic retroviral vector encoding human IL-12 (hIL-12). Second, we have studied the distribution and survival time of neo R marker genemodified syngeneic murine fibroblasts injected i.p.; third, the therapeutic potential of murine IL-12 (mIL-12)-secreting fibroblasts was tested in an immunocompetent, syngeneic, i.p. mouse model of ovarian cancer.
MATERIALS AND METHODS

Primary cell culture
Primary cell cultures were established from 41 human solid ovarian tumor biopsies (28 carcinomas, 11 benign biopsies, and 2 borderline tumors) obtained by surgical resection. These biopsies of ϳ1 cm 3 were aseptically cut into small fragments of ϳ1 mm 3 and seeded as explants in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine sera (FBS), 2 mM L-glutamine, 100 IU/mL penicillin, and 100 g/mL streptomycin in a tissue culture incubator at 37°C, 5% CO 2 , and 90% relative humidity. Nineteen of these cultures were further supplemented with 40 mU/mL epithelial growth factor (Sigma, Saint Quentin Fallavier, France), 40 mU/mL human insulin (Novo Nordisk, BoulogneBillancourt, France), and 40 mU/mL cholera toxin (Sigma).
Similarly, a primary cell culture designated RP1 was established from peritoneal tissue obtained from an 8-week-old female CBA mouse (IFFA Credo, L'Arbresle, France) and cultured in DMEM supplemented with 10% FBS, L-glutamine, antibiotics as described above.
Cultures were expanded, frozen, stored in liquid nitrogen, and used for further analysis.
Unless otherwise specified, cell culture reagents were purchased from Life Technologies (Cergy Pontoise, France).
Culture of established cell lines
The human epithelial ovarian cancer cell line OAW28 (catalog no. 85101601; European Collection of Animal Cell Cultures, Salisbury, UK) was cultured in DMEM supplemented with 10% FBS, L-glutamine, and antibiotics as described above.
The murine fibroblast cell line NIH 3T3 (catalog no. 93061524; European Collection of Animal Cell Cultures) and amphotropic ⌿CRIP packaging cells 29 (a kind gift of Dr O. Danos, Généthon, Evry, France) were cultured in DMEM supplemented with 10% heat-inactivated newborn calf sera, L-glutamine, and antibiotics as described above.
The murine epithelial ovarian cancer cell line ID8, syngeneic to C57BL/6 mice (a kind gift of Professor P. Terranova, University of Kansas Medical Center, Kansas City, Kan) was cultured in DMEM supplemented with 4% FBS, 1ϫ ITS media supplement (bovine insulin (5 mg/L), human transferrin (5 mg/L), and sodium selenite (5 g/L); Sigma), and antibiotics as described above.
The murine fibroblast cell lines MC57 and MC57 mIL-12, syngeneic to C57BL/6 mice (kindly provided by Dr. B. Couderc and V. Douin-Echinard, Centre Claudius Regaud, Toulouse, France) were maintained in RPMI 1640 medium supplemented with 10% FBS, L-glutamine, and antibiotics as described above.
Analysis of primary cell cultures by immunohistochemistry
All primary cell cultures were examined microscopically to determine cellular morphology. Five primary human cell cultures (four derived from ovarian papillary adenocarcinomas and one derived from a borderline ovarian tumor) and murine RP1 cells were stained immunohistochemically with antibodies to the epithelial cell marker cytokeratin (clone MNF116, immunoglobulin G1 (IgG1), diluted 1/50 in phosphate-buffered saline (PBS); Dako, Trappes, France), to vimentin (clone V9, IgG2a, diluted 1/100 in PBS; Dako), and to the ovarian tumor marker CA125 (clone OC125, IgG1, neat; CISbio International, Gif-sur-Yvette, France) for 1 hour at room temperature. A 1/150 dilution in PBS of the second-step "MultiLink" reagent (biotinylated swine anti-goat, anti-mouse, anti-rabbit IgG; Dako) was used followed by the third-step reagent streptavidin-biotin conjugated to horseradish peroxidase (Dako) and staining with the horseradish peroxidase substrate 3-amino-9-ethylcarbazole (Dako). Finally, slides were counter-stained with hematoxylin, and coverslips were mounted using Faramount (Dako).
The human epithelial ovarian cancer cell line OAW28 and the murine fibroblast cell line NIH 3T3 were used as controls for these procedures.
Tumorigenicity of primary cell cultures derived from human solid ovarian tumor biopsies in nude mice
The five primary human cell cultures analyzed immunohistochemically were also tested for their tumorigenicity in nude mice. For each primary cell culture, 15 female Swiss nu/nu nude mice (5 to 8 weeks of age; IFFA Credo) were injected subcutaneously (s.c.) ventrally with 5 ϫ 10 6 cells in 100 L of PBS; mice were maintained in a pathogen-free environment. At 4 weeks postinjection (p.i.) animals were sacrificed and analyzed macroscopically for the presence of tumor nodules. Tissues around the site of injection (skin and peritoneum) were collected and embedded in paraffin. Sections (3-4 m) were cut, stained with hematoxylin-eosin-safran (HES), and analyzed for the presence of tumor nodules.
The human ovarian cancer cell line OAW28 was used as a positive control for these experiments.
Vectors and retroviral infections
The polycistronic retroviral plasmid pTFG-hIL-12 30 (kindly provided by Dr. B. Couderc, Centre Claudius Regaud) is a Moloney murine leukemia virus-based vector containing cDNA of both the human p40 and p35 IL-12 subunits and neo R . The retroviral plasmid pLXSN 31 is a Moloney murine leukemia virus-based vector containing the neo R marker gene under the transcriptional control of the simian virus 40 early promoter. Neo R renders transduced eukaryotic cells resistant to the neomycin analog G418.
The retroviral plasmids pTFG-hIL-12 and pLXSN were transfected into ⌿CRIP packaging cells using the standard calcium phosphate coprecipitation technique, 32 followed by selection with complete medium containing 1 mg/mL G418 (Geneticin; Life Technologies). G418-resistant clones were isolated, expanded, and screened for viral titers. The clones with the highest retroviral titers on NIH 3T3 cells (5 ϫ 10 5 and 1 ϫ 10 8 colony-forming units/mL, respectively) were used for retroviral infections of human primary cultures and murine RP1 cells, respectively, as described elsewhere. 33 Mixed cultures of transduced (G418-resistant) cells were used in subsequent experiments.
The clone of MC57 mIL-12 cells used in our studies, secreting 1 ng of mIL-12/10 6 cells/48 hours, had been transduced with the polycistronic retroviral vector pTFG-mIL-12, 15 which is similar to pTFG-hIL-12.
Quantification of hIL-12 production by transduced primary cell cultures derived from human ovarian tumor biopsies G418-resistant primary human cell cultures were seeded at 1 ϫ 10 6 cells/well in 6-well plates; next, supernatants (3 mL/well) were collected after 48 hours of incubation. Supernatant from three independent experiments was collected, and the level of hIL-12 was determined by enzyme-linked immunosorbent assay (ELISA), specific for the hIL-12 p70 heterodimer, according to the manufacturer's protocol (Immunotech, Marseilles, France). Supernatants from nontransduced cell cultures were used as a negative control for cytokine production in the same assays.
In vivo distribution and survival time of RP1-LXSN and MC57 mIL-12 fibroblasts Female CBA mice of 8 weeks of age were injected i.p. with 5 ϫ 10 6 syngeneic RP1 fibroblasts, either nontransduced (RP1 wild-type (wt)) or transduced with pLXSN (RP1-LXSN) in 500 L of PBS. As a negative control, animals were injected with buffer only. Groups of five mice were sacrificed on days 1, 3, 7, 14, 21, 30, 61, 91, and 122 p.i. The following organs were collected: peritoneum, ovaries/uterus/omentum, intestines/ mesentery/pancreas, liver, spleen, kidneys, stomach, diaphragm, and lungs. These samples were split in two: one-half was snap-frozen and stored in liquid nitrogen to be used for the isolation of genomic DNA and total RNA. The other half was fixed in neutral-buffered formalin for a maximum of 24 hours, embedded in paraffin, and used for histological examination and genomic DNA extraction from sections. These in vivo experiments were performed one to three times with groups of five mice.
A similar experiment was performed using MC57 and MC57 mIL-12 fibroblasts. Five million cells per mouse were injected i.p. in female syngeneic C57BL/6 mice (8 weeks of age; IFFA Credo). Groups of five animals were sacrificed on days 7, 14, 21, and 30 p.i. The same organs as described above were collected, and paraffin-embedded sections were prepared from all samples. Genomic DNA was only extracted from samples collected from the group sacrificed 30 days after i.p. injection of MC57 mIL-12 cells.
Detection of neo
R by polymerase chain reaction (PCR), reverse transcription (RT)-PCR, and Southern blot hybridization Genomic DNA and total RNA were extracted from frozen samples using TRIzol reagent (Life Technologies). Briefly, samples were defrosted in TRIzol reagent, cut into small pieces, and homogenized with an Ultra-Turrax homogenizer (Janke & Kunkel IKA Labortechnik, Staufen, Germany). Subsequently, the TRIzol reagent extraction protocol was followed.
For the detection of i.p. injected, neo R -containing RP1-LXSN or MC57 mIL-12 fibroblasts, 500 ng of genomic DNA template prepared from the different organs was used in a multiplex PCR. In addition to neo R -specific primers (neo), a primer pair amplifying a fragment of exon 1 of the murine ␥-actin gene (m␥-actin) was included in all reactions as a control for DNA quality. The following primers were used: neo sense, 5Ј-GAT GGA TTG CAC GCA GGT TC-3Ј; neo antisense, 5Ј-GCA TTG CAT CAG CCA TGA TG-3Ј; m␥-actin sense, 5Ј-AGA GAG ACT CCT AGA CTG ACT G-3Ј; and m␥-actin antisense, 5Ј-TAT GCA GAA GGA TTC AGT G-3Ј. PCR products were analyzed by electrophoresis on agarose tris(hydroxymethyl)aminomethane-borate-ethylenediaminetetraacetic acid gels containing ethidium bromide. The expected sizes for amplification of the neo R and m␥-actin fragments were 347 and 815 bp, respectively. For each experiment, negative controls (one without DNA and another with genomic DNA isolated from cultured RP1 or MC57 wt cells) and positive controls (genomic DNA isolated from cultured RP1-LXSN or MC57 mIL-12 cells, and pLXSN plasmid DNA) were included.
Total RNA (1 g per sample) was digested with 1 U of ribonuclease-free deoxyribonuclease I (amplification grade; Life Technologies) to ensure complete removal of contaminating genomic DNA. First-strand cDNA was prepared using the first-strand cDNA synthesis kit (Life Technologies) according to the manufacturer's instructions; however random hexamer primers at 10 ng/L (Amersham Pharmacia Biotech, Orsay, France) were substituted for oligo(dT) [12] [13] [14] [15] [16] [17] [18] .
RT-PCR was performed on one-fifth of the resulting firststrand cDNA using the same neo R -specific primers as above, but replacing the m␥-actin-specific primers with primers specific for murine glyceraldehyde-3-phosphate dehydrogenase (mGAPDH) (mGAPDH sense, 5Ј-GCA CCA CCA ACT GCT TAG-3Ј; mGAPDH antisense, 5Ј-ATG GAA ATT GTG AGG GAG A-3Ј) as a control for the quality of the first-strand cDNA. RT-PCR products were analyzed by agarose gel electrophoresis as described above. The expected size for amplification of the mGAPDH fragment was 650 bp.
To exclude residual contamination with genomic DNA in the RNA preparations, PCR amplifications were also performed on all total RNA samples (without RT). A negative control (without DNA) and positive controls (first-strand cDNA prepared from cultured RP1-LXSN cells and pLXSN plasmid DNA) were also included in all experiments. Southern blotting of PCR products was performed using standard methodology. 32 For detection, the enhanced chemiluminescence labeling and detection system (Amersham Pharmacia Biotech) was used according to the supplier's recommendations. The probe used was a 728-bp neo R fragment obtained by digestion of pLXSN with NcoI.
Analysis of paraffin-embedded sections by histochemistry and PCR
Paraffin blocks were cut into serial 3-m sections, mounted onto slides, and stained with HES. Stained slides were examined for the presence and localization of RP1, RP1-LXSN, MC57, or MC57 mIL-12 cells by a pathologist.
We selected five HES-stained paraffin sections for the presence of groups of fibroblast-like cells (two from tissue collected 7 days after i.p. injection of RP1-LXSN cells, two from tissue collected 14 days after i.p. injection of RP1-LXSN cells, and one containing tissue collected 14 days after i.p. injection of nontransduced RP1 cells). As controls, cell pellets from cultured RP1 and RP1-LXSN cells were embedded in paraffin.
Genomic DNA from these paraffin-embedded samples was obtained as follows: Five 10-m sections were used per DNA extraction. The region of interest (containing groups of fibroblast-like cells) was marked with the help of an HES-stained slide. The paraffin-embedded tissue outside the region of interest was removed from the slides using a sterile scalpel. Subsequently, slides were deparaffinized in two toluene baths and one absolute ethanol bath for 5 minutes each. Marked regions were recovered from slides using a sterile scalpel and resuspended in extraction buffer (20 mM tris(hydroxymethyl) aminomethane-HCl (pH 8), 10 mM ethylenediaminetetraacetic acid (pH 8), 10 mM NaCl, and 0.6% sodium dodecyl sulfate). Proteinase K was added to a final concentration of 0.5 mg/mL, and tubes were incubated at 60°C overnight. After inactivation of proteinase K at 100°C for 10 minutes, tubes were incubated for 5 minutes at 4°C and NaCl was added to a final concentration of 1.8 M. Tubes were centrifuged at 12,000 ϫ g for 10 minutes at room temperature to remove debris and precipitated proteins. Genomic DNA was precipitated from supernatants using two volumes of absolute ethanol and 130 ng/L glycogen (Roche Molecular Biochemicals, Meylan, France) as a carrier. Pellets were washed with 70% ethanol, dried, and dissolved in 20 L of sterile distilled water. PCRs were performed as described above for genomic DNA.
Effect of MC57 fibroblasts secreting mIL-12 on immunocompetent syngeneic mice inoculated with ID8 ovarian cancer cells Three groups of female C57BL/6 mice (8 weeks of age) were injected i.p. with 1 ϫ 10 6 ID8 ovarian cancer cells (resuspended in 500 L of DMEM without supplements) in one flank. The first group of animals was left untreated or injected i.p. with DMEM in the opposite flank. The second group received ID8 cells followed by a single i.p. injection of 1 ϫ 10 7 MC57 cells (resuspended in 500 L of DMEM without supplements) per mouse in the opposite flank, whereas the third group received a single i.p. injection of 1 ϫ 10 7 MC57 mIL-12 cells secreting a total of 10 ng of mIL-12/48 hours (resuspended in 500 L of DMEM without supplements) in the other flank. This experiment was performed twice, the first time with five mice per group and the second time starting with 25 mice per group. Before injection, mIL-12 production by MC57 mIL-12 fibroblasts was confirmed using an mIL-12 p70 ELISA kit (Genzyme Diagnostics, Cambridge, Mass).
A subset of mice was killed at different times p.i. and analyzed for tumor development. The remaining animals were followed daily for survival analysis. Mice with apparently advanced disease (development of ascites and impaired mobility) were sacrificed by cervical dislocation and were considered to have died on the day of the sacrifice. Mice sacrificed at the end of the study (150 days p.i. in the first experiment and 120 days p.i. in the second experiment) and without external signs of advanced neoplastic disease were considered alive at the day of sacrifice. The peritoneal and pulmonary cavities of all mice were examined macroscopically for the presence of tumor nodules, and peritoneal organs and lungs were collected. In the second experiment, diaphragms were weighed. HES-stained, paraffin-embedded sections were prepared as described above and analyzed for the presence and appearance of tumor nodules.
Statistical analyses
Survival analyses were performed using Kaplan-Meier's method. Mice culled for comparison of tumor development and without signs of advanced neoplastic disease were considered to be alive for calculation of the percentage of survival. Statistical comparisons were made using the log-rank test. The Kruskal-Wallis H-test was selected for the analysis of diaphragm weights.
RESULTS
Analysis of primary cell cultures
Primary human cell cultures were established from explants of 41 human solid ovarian tumor biopsies. These primary cultures were successfully expanded to at least a second passage in 38 of 41 cases (93%); in the three remaining cultures (one derived from a malignant ovarian tumor biopsy and two derived from benign ovarian tumors), no proliferating cells were obtained. All 38 cultures grew as monolayers of adherent cells and exhibited fibroblastic morphology. None of these cultures contained cells with epithelial morphology, even though 19 of the cultures were supplemented with epithelial growth factor, insulin, and cholera toxin to favor epithelial cell proliferation.
Similarly, the RP1 primary cell culture, established from peritoneal tissue obtained from a CBA mouse, exhibited fibroblastic characteristics ( Table 1) .
Five of the human primary cultures were expanded and analyzed more extensively by immunohistochemistry. These selected human primary cell cultures, the murine RP1 primary cell culture, and the NIH 3T3 fibroblast cell line expressed vimentin but not cytokeratin (epithelial cell marker), whereas the OAW28 epithelial ovarian cancer cell line only expressed cytokeratin. Furthermore, the primary human cell cultures, in contrast to the ovarian cancer cell line OAW28, did not express CA125 (ovarian cancer marker) (Table 1) , even though immunohistochemistry on sections of the origi-nal tumor biopsies revealed expression of CA125 (data not shown).
Tumorigenicity of primary cell cultures derived from human solid ovarian tumor biopsies in nude mice
The five primary cell cultures obtained from human solid ovarian tumor biopsies analyzed immunohistochemically were also tested for their tumorigenicity in nude mice. At 4 weeks after s.c. injection into nude mice, the OAW28 ovarian cancer cell line produced tumors with a diameter of between 0.5 and 1 cm at the site of injection, whereas no tumor nodules were observed in mice injected with human primary cell cultures. Microscopic analysis of HES-stained, paraffin-embedded sections showed the presence of tumor nodules in the control group (OAW28), whereas the skin and peritoneum samples of mice injected with human primary cell cultures were tumor-free ( Table 1) .
Quantification of hIL-12 production by transduced primary cell cultures derived from human ovarian tumor biopsies The same five primary cultures analyzed previously were transduced with the polycistronic retroviral vector pTFG-hIL-12. Mixed cultures of transduced cells were obtained after G418 selection. Supernatants collected from these cultures contained high levels (ranging between 82.3 Ϯ 11.2 and 162 Ϯ 10.7 ng/10 6 cells/48 hours) of hIL-12 p70 heterodimer for at least 21 days, as revealed by hIL-12 p70-specific ELISA (Table 1) . No hIL-12 p70 could be detected in supernatants collected from nontransduced primary cultures (data not shown).
Detection of RP1-LXSN or MC57 mIL-12 fibroblasts using PCR, RT-PCR, and Southern blot hybridization
For the detection of RP1-LXSN or MC57 mIL-12 fibroblasts injected i.p. in syngeneic mice, genomic DNA isolated from the different organs was studied for the presence of neo R by PCR. The photographs of agarose gels in Figure 1A show that neo R could be detected in the intestines/mesentery/ pancreas samples at days 61 and 91 after the injection of RP1-LXSN, but not at 122 days p.i. A neo R -specific band was also obtained in liver samples of mice sacrificed at 61 days p.i., but not 91 or 122 days p.i., whereas no neo R -band was present in the lung samples of any of these mice. The absence of neo R -specific bands was not due to degradation of the genomic DNA or suboptimal PCR conditions, because all samples amplified the m␥-actin-specific 815-bp fragment, and the 347-bp neo Rspecific fragment was amplified in the positive controls, genomic DNA from cultured RP1-LXSN cells (labeled RP1-LXSN) and pLXSN plasmid DNA (labeled pLXSN). Table 2 summarizes the PCR results for all mice. This table shows that RP1-LXSN cells were initially associated with many organs and tissues in the peritoneal cavity, but survived for Ͼ30 days only when attached to the intestines/mesentery/pancreas (100% of mice at 30 days p.i.) and liver (80% of mice at 30 days p.i.). At 91 days p.i., these cells were found to be associated only with the intestines/mesentery/pancreas (33% of mice), and at 122 days p.i., all genomic DNA samples were negative for neo R . Only one lung sample (day 1 p.i.) was found to be positive for neo R . Using Southern blot analysis with a neo R -specific probe on some of the gels, the 347-bp fragment was validated to be a neo R frag- Similarly, all genomic DNA samples isolated from liver and intestines/mesentery/pancreas samples collected from C57BL/6 mice 30 days after injection with MC57 mIL-12 cells were shown to be positive for neo R (data not shown).
RT-PCR was performed on first-strand cDNAs prepared from all samples collected at 61 days, 91 days, and 122 days after i.p. injection of RP1-LXSN cells (Fig 1B) . Multiplex RT-PCR was performed using the same neo R -specific primers as described above as well as primers specific for mGAPDH as a control for the quality of first-strand cDNA. The absence of bands after PCR on samples that were not reverse transcribed (indicated by a Ϫ) demonstrates the absence of contaminating genomic DNA. All samples that underwent RT-PCR (indicated by a ϩ) amplified the 650-bp mGAPDH band, affirming the good quality of the first-strand cDNA. The 347-bp neo R -specific band was amplified in the positive controls RP1-LXSN and pLXSN, in the intestines/mesentery/pancreas samples at 61 and 91 days p.i. but not at 122 days p.i., and in the liver sample at 61 days p.i. but not at 91 or 122 days p.i. No amplification was observed in any of the lung samples.
As expected, RT-PCR was more sensitive than PCR on genomic DNA with regard to the detection of RP1-LXSN cells. Using serial dilutions, we showed that the detection limit of PCR on genomic DNA using neo R -specific primers followed by Southern blot hybridization is 100 RP1-LXSN cells in a total of 10 7 cells, whereas 1 cell in a total of 10 7 cells can be detected by RT-PCR followed by Southern blot hybridization for neo R (data not shown). This explains why more samples were found to be neo 
Analysis of paraffin-embedded sections by histochemistry and PCR
Histological examination of HES-stained, paraffin-embedded sections showed nodules of fibroblast-like cells attached to the peritoneum, omentum, mesenteric fat, and liver hilus 1 day after i.p. injection of RP1 or RP1-LXSN cells; these nodules were attached to the mesenteric fat and liver hilus at 3 days p.i., to the peritoneum and mesenteric fat at 7 days p.i., and only to the mesenteric fat at 14 and 21 days after i.p. injection of RP1 or RP1-LXSN cells. Many nodules of fibroblast-like cells were invaded by mononuclear cells, and some of them showed necrotic areas. These phenomena were observed in mice injected with either RP1 or RP1-LXSN cells. No foci of fibroblast-like cells could be detected in sections collected at Ն30 days p.i. (data not shown). Similar results were obtained with MC57 and MC57 mIL-12 fibroblasts injected in C57BL/6 mice (data not shown). Figure 2A shows representative HES-stained sections containing such nodules attached to the mesenteric membranes close to the colon, pancreas, or peritoneum at 7 and 14 days after i.p. injection of RP1-LXSN or RP1 cells. Note that these fibroblasts are attached to organs but do not invade the underlying tissues. All sections reveal peripheral mononuclear infiltrates, whereas section 3 shows both necrosis at the center of the nodule and a mononuclear infiltrate surrounding it. Figure 2B shows agarose gel electrophoresis after multiplex PCRs on genomic DNA samples isolated from the paraffin-embedded sections shown in Figure 2A , as described in Materials and Methods. The 815-bp m␥-actin fragment was amplified from all genomic DNA samples isolated from paraffin-embedded sections (RP1 wt, RP1-LXSN, and samples from sections 1-7). The 347-bp neo R -specific fragment was amplified from the positive controls, genomic DNA isolated from paraffinembedded cultured RP1-LXSN cells (labeled RP1-LXSN) and pLXSN plasmid DNA (labeled pLXSN). All paraffin-embedded sections of samples derived from mice injected with RP1-LXSN cells were also positive for neo R , whether at 7 days p.i. (photographs 1 and 2) or at 14 days p.i. (photographs 3-6), confirming that the nodules of fibroblast-like cells observed in the HESstained, paraffin-embedded sections (Fig 2A) were indeed the i.p. injected RP1-LXSN cells. In contrast, no neo R -specific fragment could be amplified from the sample collected 14 days after injection of unmodified RP1 cells (negative control; photograph 7).
Effect of treatment on the survival time of mice in the ID8 model of ovarian cancer In a pilot experiment, using groups of five C57BL/6 mice, a statistically significant improvement in survival time was observed for mice treated with MC57 mIL-12 fibroblasts (secreting a total of 10 ng of mIL-12/48 hours) injected the same day as ID8 ovarian cancer cells, relative to the combination of mice injected with only ID8 cells or treated with ID8 and wt MC57 fibroblasts (log-rank test, P ϭ 0.0027). There was no statistically significant difference in survival time between the latter two groups. A total of 80% of mice treated with MC57 fibroblasts secreting mIL-12 did not show external signs of neoplastic disease at 150 days p.i., when all mice of the other groups had been sacrificed because of advanced neoplastic disease.
We repeated this experiment starting with groups of 25 mice and with a slight modification for the control group. Unlike in the first experiment, control mice received an injection of medium, rather than being left untreated.
As shown in Figure 3 , the results of the pilot experiment were confirmed, with a statistically significant improvement in the survival of MC57 mIL-12-treated mice relative to mice treated with medium or wt MC57 (P Ͻ 10 Ϫ5 , log-rank test). In fact, animals treated with MC57 mIL-12 fibroblasts showed 88% survival, and none of the 11 animals of this group remaining at day 120 p.i. showed external signs of neoplastic disease. At that time, most of the animals in the other groups had been culled because of advanced neoplastic disease (medium group: 16% survival; MC57 group: 0% survival at 120 days p.i.). No statistically significant difference was observed between mice treated with either medium or nontransduced fibroblasts (P ϭ 0.28, log-rank test). Five mice treated with wt MC57 cells died spontaneously at 15 or 16 days p.i. Unfortunately, the poor quality of the tissues collected from these mice did not allow determination of the cause of death. However, these deaths occurred too early to be cancer-related in this model, and the fact that all five mice originated from the same cage suggests that they died from an infectious disease. The exclusion of these five mice does not significantly change the statistical results (data not shown).
Effect of treatment on tumor burden in the ID8 model of ovarian cancer
To compare tumor development, small numbers of mice from all groups were sacrificed before external signs of cancer (days 22 and 37 p.i.) or when mice in at least one group needed to be euthanized as a result of advanced neoplastic disease (days 71, 79, 84, 95, and 99 p.i.). The experiment was terminated at 120 days p.i. with the sacrifice of the remaining animals.
Up to and including day 37 p.i., no tumor nodules were observed in mice treated with MC57 mIL-12, whereas small intestinal tumor nodules were macroscopically visible in both sacrificed animals of the medium-treated group at 22 days p.i., and small tumor nodules attached to the liver and diaphragm were visible for one of two of the MC57-treated mice at this time. A peritoneal tumor nodule was observed in one of three of both MC57-and medium-treated mice at LXSN cells (3-6) , or 14 days after the injection of unmodified RP1 cells (7). 1,2: Fibroblast nodules attached to the mesentery. 3: A fibroblast nodule attached to the 37 days p.i. At day 71, a few small tumor nodules attached to the peritoneum (for one mouse) and near the liver (for the other mouse) were visible for the first time in sacrificed MC57 mIL-12-treated mice (no external signs of disease). However, around that time, mice in the other two treatment groups were developing ascites and had tumor nodules attached to most peritoneal organs, for which some of them needed to be culled. This difference (limited or no neoplastic disease in the case of MC57 mIL-12-treated animals and advanced peritoneal neoplastic disease in the case of mice of the other two groups) continued until the end of the experiment. In fact, 4 of the 11 remaining mice treated with MC57 mIL-12 were completely tumor-free at day 120 p.i., and the other 7 showed limited tumor development. In total, only two mice from this group succumbed to cancerous disease. By contrast, all MC57-treated mice (other than the ones sacrificed for comparison and without external signs of advanced disease) needed to be culled at Յ120 days p.i. The three mice from this group that were sacrificed at day 120 p.i. and the three remaining mediumtreated mice (without external signs of advanced disease) had widespread peritoneal cancer. It is noteworthy that some of the tumor nodules observed from day 95 p.i. onward in the MC57-or medium-treated groups were colored red, whereas this was never observed for the MC57 mIL-12-treated mice (data not shown). Tumor nodules were not detected in any of the lung samples.
Apart from the qualitative assessment of tumor development based on macroscopy described above, we wanted a quantitative measure of the extent of neoplastic disease in the peritoneal cavity. In the first pilot animal experiment, we noticed that the number of tumor nodules on the diaphragm seemed to be an indicator for the disease state of the animal. In the repeat experiment, we therefore weighed diaphragms as a quantitative measure of tumor burden.
When the diaphragm weights of the different groups were compared, a statistically significant difference between mice treated with MC57 mIL-12 fibroblasts and mice treated with medium (P ϭ .018; H-test) or mice treated with MC57 wt fibroblasts (P ϭ .0016; H-test) was observed. However, no statistically significant difference between the latter two groups existed (P ϭ .18, H-test). As shown in Table 3 , the average diaphragm weight of the MC57 mIL-12-treated mice was 35% lower than that of the mock-treated mice, even though these samples were collected later than for the other two groups.
Histological analysis of HES-stained, paraffinembedded tissue sections for the presence and appearance of tumor nodules in the ID8 model of ovarian cancer Histological analysis of HES-stained, paraffin-embedded tissue sections prepared from the same mice analyzed macroscopically (see above) showed that for the mice sacrificed on days 22 and 37 p.i., no microscopic tumor nodules were found in those animals that were macroscopically tumor-free, whereas the nodules in tumorbearing animals were implanting themselves in the underlying tissues. From day 71 p.i. onward, tumor nodules showed numerous mitoses, invasive behavior, few areas of necrosis, and minor peripheral lymphocyte infiltration in the MC57-or medium-treated mice. Red tumor nodules were shown to contain extensive neovasculature. In contrast, tumor nodules found in MC57 mIL-12-treated mice contained many areas of necrosis and atypically large tumor cells. Furthermore, inflammatory reactions (comprising macrophages, plasmocytes, and polynuclear granulocytes) directed against these nodules were observed. At day 120 p.i., no evidence of tumor growth could be found in the four macroscopically tumor-free animals (MC57 mIL-12 group). The sections , log-rank test) compared with mice treated with either medium or nontransduced fibroblasts. No statistically difference was observed between both control groups (P ϭ .28, log-rank test). The experiment was started with 25 mice per group, but some mice from the different groups without external signs of advanced neoplastic disease were euthanized for comparative reasons or at the end of the experiment (day 120 p.i.). This is indicated by a small vertical line on the appropriate curve, accompanied by the number of animals culled.
serosa of the colon, necrosed centrally, and with a peripheral inflammatory infiltrate. 4 -6: Details of fibroblast nodules attached to the peritoneal lining (4), mesentery (5), and pancreas (6) (all derived from the same section). 7: Nodule implanted in the mesentery. Arrows indicate inflammatory infiltrates, whereas the arrowhead indicates an area of necrosis. Magnifications: 1,3,7: ϫ100 magnification; 2,4,5: ϫ250 magnification; 6: ϫ280 magnification. B: Agarose gel electrophoresis of multiplex PCRs performed on genomic DNA samples isolated from the paraffin-embedded sections shown in (A).
of the other animals treated with MC57 mIL-12 and showing a few small tumors at day 120 p.i. revealed that these small tumor nodules were surrounded by a dense lymphocyte infiltrate (Fig 4, A-C) . These nodules were poorly vascularized and necrosed in the center (Fig 4C) . In addition, we observed hyperplastic mesenteric lymph nodes and activated Peyer's patches, as well as expanded white pulp on spleen sections. In contrast, animals treated either with medium or MC57 cells developed well-vascularized ( Fig 4D) and invasive ( Fig 4E) tumor nodules without necrosis and with only a small, peripheral lymphocyte infiltrate. No expanded splenic white pulp and only a few hyperplastic mesenteric lymph nodes and activated Peyer's patches were observed in HES-stained tissue sections from mock-treated mice. All analyzed lung sections were free of tumor cells.
Signs of IL-12-induced toxicity (tissue necrosis in the liver, spleen, or lungs) were not observed in any of the appropriate HES-stained, paraffin-embedded tissue sections analyzed.
DISCUSSION
Most ovarian cancer patients receiving conventional therapy, usually surgical resection followed by chemotherapy, still have a poor prognosis. Thus, the development of additional therapeutic strategies as a secondary treatment after surgery appears to be necessary. One such additional strategy may be gene therapy. [3] [4] [5] [6] [7] In vivo gene transfer lacks specificity and/or efficacy for malignant cells at present. 8, 9 However, ex vivo gene transfer can be achieved by a wide variety of gene therapy vectors. Unfortunately, it is only possible to culture ovarian cancer cells in a small percentage of cases, and almost exclusively from ascites, not from solid tumor biopsies. 27, 28 We did not obtain any epithelial cell cultures from 41 solid ovarian tumor biopsies either, not even with cell culture conditions favoring epithelial cell growth. However, we have obtained fibroblast-like cell cultures from 38 (93%) of these biopsies. Five of these cultures were examined further and shown to stain positively for vimentin and negatively for the epithelial marker cytokeratin and ovarian cancer marker CA125. These cells did not form tumors in nude mice and, after transduction with a polycistronic retroviral vector encoding hIL-12, produced high levels of hIL-12 for at least 3 weeks.
From these primary culture experiments, we concluded that ex vivo ovarian cancer gene therapy using autologous epithelial tumor cells obtained from solid tumor biopsies is not feasible, because the culture of such tumor cells is very difficult. In contrast, primary fibroblast cultures might constitute a suitable vehicle for regional gene therapy for ovarian cancer. A number of advantages of autologous fibroblasts relative to autologous tumor cells for gene therapy purposes have been described. As in our study, primary fibroblast cultures are in general easily obtained, and these cultures can readily be transduced. 34 -37 When transduced with a cytokine gene, fibroblasts secrete higher levels of this cytokine than tumor cells transduced in the same manner. 37 This finding is in agreement with the high levels of hIL-12 secreted by our primary cultures transduced with a retroviral vector.
To study the feasibility of using these fibroblasts as a vehicle for regional, i.p. ovarian cancer gene therapy, we have first examined the behavior of neo R marker genetransduced syngeneic murine fibroblasts injected i.p. Our results show that i.p. injected syngeneic fibroblasts remain in the peritoneal cavity for a prolonged period (30 days), attached to the pancreatic and hepatic mesentery, and continue to express neo R as long as they are present in vivo. At 122 days p.i., we could no longer detect these injected fibroblasts. Importantly, these fibroblasts do not invade the underlying tissue and do not generally migrate to the lungs. This is in agreement with other studies that have shown that fibroblasts have low migratory potential and are not neoplastic. 35, 38 In contrast, transduced tumor cells need to be lethally irradiated before readministration, to prevent neoplastic disease derived from these gene-modified tumor cells. 39 Many fibroblast nodules were invaded by mononuclear cells, and some nodules showed necrotic areas. These phenomena were observed in mice injected with either RP1-LXSN, MC57 mIL-12, unmodified RP1, or MC57 cells. This proves that they are dependent upon the injection of these cells, but independent of transduction with retroviral vectors. Immune infiltrates and necrosis may explain the gradual disappearance of these fibroblasts from the peritoneal cavity. In fact, the emergence of a mononuclear infiltrate may be induced by *Results of diaphragm weights for the different treatment groups, as a quantitative measure of tumor burden. A statistically significant difference between the diaphragm weights of mice treated with MC57 mIL-12 fibroblasts compared with mice treated with medium (P ϭ .018; H-test) or mice treated with MC57 wt fibroblasts (P ϭ .0016; H-test) was observed. However, no statistically significant difference between the latter two groups exists (P ϭ .18; H-test). Note that the average diaphragm weight of the MC57 mIL-12-treated mice is the lowest of the three groups, even though these samples were on average taken later than for the other two groups.
necrosis of some of the injected fibroblasts, which fail to adapt to the in vivo environment or are not sufficiently close to vascularization.
This gene marker study, although not studying the therapeutic effect in and of itself, established, to our knowledge for the first time, the distribution and survival of syngeneic gene-modified fibroblasts injected i.p., as well as the long-term expression of the transgene. The persistence of these fibroblasts in the peritoneal cavity suggests that human autologous fibroblasts may be a useful vehicle for regional i.p. delivery of cytokines as an additional method to treat ovarian cancer or other malignancies with peritoneal dissemination. Furthermore, their gradual disappearance may permit their injection as live cells, allowing long-term expression of the transgene. Nevertheless, for the injection of live, autologous fibroblasts, a safety feature, such as transduction with a suicide gene, may be a requirement. Such a gene will permit killing of the reinjected cells in case of undesirable side effects. Therefore, we recently constructed a retroviral vector that permits simultaneous expression of a therapeutic gene (e.g., encoding a cytokine) and a suicide gene. 40 The lack of inbred, immunocompetent mouse models for ovarian cancer has limited studies of the in vivo effect of immunostimulatory cell vaccines. Several investigators have used immunodeficient mice to study the effect of cytokine gene therapy for ovarian cancer. In the majority of these studies, human ovarian cancer cells were injected s.c. into such animals. 4, 41 The ID8 ovarian cancer model used in our study has the advantage that it is an immunocompetent model; in addition, the peritoneal dissemination of the ID8 ovarian cancer cells closely resembles the clinical situation.
Continuing on from our preliminary results, and based on the positive results obtained with IL-12-secreting fibroblasts in several animal cancer models, [42] [43] [44] we have studied the efficacy of mIL-12-secreting fibroblasts injected i.p. (in one flank) on the same day as tumor cells (injected i.p. in the opposite flank) in the ID8 ovarian cancer model. To our knowledge, this is the first report using IL-12-secreting fibroblasts in such a model as a vehicle for regional, i.p. gene therapy for this neoplastic disease. The number of MC57 mIL-12 cells used for treatment (secreting 10 ng/10 7 cells/48 hours) was based on results of Zitvogel et al, 44 who established the minimal effective dose for bioactive IL-12 as 150 ng/kg body weight. Our results show a statistically significant decrease in diaphragm weight for the MC57 mIL-12-treated animals compared with the control groups (treated with medium or unmodified MC57 cells) as a measure for tumor burden. Because the diaphragms from mice treated with MC57 mIL-12 were on average collected later than for the other two groups, and assuming a progressive increase in tumor burden over time, the diaphragm weights of the MC57 mIL-12-treated mice would be expected to be the highest. Therefore, mice treated with MC57 mIL-12 fibroblasts have a significantly reduced tumor burden compared with those treated with medium or MC57 wt cells. A statistically significant increase in the survival of mice treated with a single i.p. injection of mIL-12-secreting fibroblasts relative to mice treated with medium or unmodified fibroblasts was also observed.
Antitumoral effects of paracrine secretion of cytokines by genetically transduced fibroblasts have already been observed in a variety of tumor establishment and vaccination models, and with different cytokines. 39,42,44 -48 With regard to IL-12 gene therapy, Zitvogel et al 44 have reported that IL-12-secreting syngeneic or allogeneic fibroblasts injected s.c. could efficiently treat animals with large established tumors (MCA207 sarcoma, MC38 colorectal carcinoma, or the poorly immunogenic MCA102 sarcoma) in situ or at distant sites (i.e., s.c. tumor deposits or lung metastases) and promote specific long-term antitumoral immunity in a dose-dependent manner. Weekly inoculations for 3 weeks could also be used to effectively treat a day 4 MCA207 sarcoma located intradermally in the opposite flank (80% protection using syngeneic fibroblasts). No toxicity associated with repeated injections of IL-12-secreting fibroblasts was observed. In our study, we did not observe any signs of IL-12-induced toxicities either, such as weight loss, fur ruffling, lethargy, or tissue necrosis in the liver, spleen, or lungs, as observed in systemically treated mice 17, 18, 49 or humans. 17, 18 Therefore, the pharmacokinetic profile of IL-12 produced by genetically engineered fibroblasts appears to be superior to injected recombinant IL-12 in terms of toxicity, without apparent loss of efficacy.
IL-12 is thought to induce two antitumoral mechanisms: (a) antitumoral immunity via direct activation of antitumoral natural killer cells and T lymphocytes that possess specific IL-12 receptors 19, 20 and (b) anti-angiogenesis, resulting in decreased blood supply to tumors, thereby starving them. 24, 25, 50 Our histological data show preliminary evidence for both of these mechanisms being implicated in the antitumoral effect of the IL-12-secreting fibroblasts in the ID8 ovarian cancer model. Namely, small, necrosed tumor nodules, poorly vascularized and with substantial macrophage and lymphocyte (plasmocytes, polynuclear granulocytes) infiltration, were observed in mice treated with IL-12-secreting fibroblasts. In contrast, tissue sections from animals treated with medium or unmodified fibroblasts showed large invasive tumor nodules, well-vascularized, with only a few areas of necrosis and a minor peripheral mononuclear infiltrate. Furthermore, spleen sections demonstrated expanded white pulp among mice treated with IL-12-secreting fibroblasts in contrast to controls. Because the white pulp is the region of the spleen in which immune effector cells proliferate, this finding suggests an immunological basis for the observed antitumoral effect among animals treated with IL-12-secreting fibroblasts. Similar results were obtained by Silver et al, 51 who found higher spleen weights in severe combined immunodeficient mice injected s.c. with specimenderived human ovarian carcinoma and treated with 20 daily i.p. injections of recombinant mIL-12 (0.33 g/day) compared with controls.
Based on the successful results described above, paracrine secretion of cytokines by fibroblasts may serve as an effective cytokine gene therapy for different types of cancers. This strategy circumvents the difficulties of routinely establishing primary tumor cells from human cancers and decreases the toxicity associated with the systemic administration of cytokines. Indeed, fibroblasts secreting cytokines are now being used in clinical gene therapy trials for malignant melanoma; 34, 35, 38, 52 breast, 34, 35, 38 colon, 34, 38, 53 and head and neck cancer; 35 renal cell carcinoma; 34, 38, 52 and cutaneous T-cell lymphoma. 35 In summary, our findings both in a clinically relevant model of ovarian cancer and with ovarian cancer biopsyderived fibroblasts suggest that such autologous fibroblasts can be used as a vehicle for the i.p. delivery of IL-12 in vivo as a secondary, regional treatment for minimal residual disease of ovarian cancer.
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